CN105861685A - Kit for testing Quetiapine application effect based on rs5993883 and application method of kit - Google Patents
Kit for testing Quetiapine application effect based on rs5993883 and application method of kit Download PDFInfo
- Publication number
- CN105861685A CN105861685A CN201610298301.6A CN201610298301A CN105861685A CN 105861685 A CN105861685 A CN 105861685A CN 201610298301 A CN201610298301 A CN 201610298301A CN 105861685 A CN105861685 A CN 105861685A
- Authority
- CN
- China
- Prior art keywords
- primer
- seq
- nucleotide
- quetiapine
- kit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention provides a kit for testing Quetiapine application effect based on rs5993883 and an application method of the kit. The single nucleotide polymorphism locus is located at NO.8375, rs5993883 (T->G). The invention further relates to primers for amplification of SNPrs5993883 on NO.4 intron of the COMT (Catechol-O-methyltransferase) gene, and the primers are as shown as SEQ ID NO:3 and SEQ ID NO:4. Compared with the prior art, the kit and the application method thereof have the advantages that a foundation for research on ABCB1 gene polymorphism and clinical medicine safety is laid, and a theoretical basis for individualization of clinical medicine and a guidance for research and development of novel medicine based on pharmacogenomics idea are provided.
Description
Technical field
The present invention relates to the test kit of the detection Quetiapine medication effect based on rs5993883 in gene technology field
And using method, specifically a kind of separation nucleic acid, a kind of allele specific nucleic acid primer and COMT
The detection method of gene SNP rs5993883 single nucleotide polymorphism.
Background technology
The chemical entitled 11-{4-of Quetiapine (Quetiapine) [2-(2-(hydroxy ethoxy) ethyl-1-piperazine] } dibenzo [b,
F] [Isosorbide-5-Nitrae] sulfur azepine1/2 fumarate, molecular formula C21H25N302S˙1/2C4H4O4.Quetiapine is a kind of novel
Psychosis, all has interaction to the various neurotransmitters receptor such as dopamine, 5-hydroxy tryptamine.Clinical research shows quinoline
Sulfur is flat not only effective to the schizophrenia positive symptom, also has certain effect to negative symptoms.Can also alleviate and spirit point
Split the relevant affective symptom of disease such as depressed, anxiety and cognitive defect symptom.Common adverse reactions is dizzy, drowsiness, upright
Property hypotension, cardiopalmus, xerostomia, inappetence and constipation.Also body weight can be caused to increase, suffer from abdominal pain, silent ALP
Increase and increase with blood T-CHOL and triglyceride.Although compared with classical psychosis, the medicine caused by Quetiapine
Although untoward reaction is less, toleration is preferable, but once generation can cause nervous system, liver and gall, digestive system
And the major injury of cardiovascular system.Research shows, the drug effect of Quetiapine and drug side effect have obvious individual variation,
Reason is that its metabolism is affected by inherited genetic factors and environmental factors, but inherited genetic factors is topmost reason.Therefore develop
The more molecular marked compound the most relevant to Quetiapine metabolism thus patient is realized individualized treatment and is necessary.
COMT (Catechol-O-methyltransferase) gene is positioned on No. 22 chromosome q11.21 of the mankind, not
Same cell is translated into the albumen of different length.In the neurocyte of brain, COMT gene expression is that film combines
Catechol O-methyltransferase albumen；Catechol O-methyltransferase albumen in brain is mainly distributed on prefrontal lobe skin
Matter district, it may ensure that neurotransmitter such as dopamine etc. are in a stable level.In the organs such as liver, kidney and blood
Being expressed as the catechol O-methyltransferase albumen of solubility, it can be catalyzed methyl and transfer to from S-adenosylmethionine
On catecholamine, this type of material includes neurotransmitter dopamine, epinephrine, norepinephrine etc..COMT gene
Play an important role in terms of the catechol medicine of hypertension, asthma, Parkinson disease is treated in metabolism.Due to Quetiapine
All there is interaction with the various neurotransmitters receptor such as dopamine, 5-hydroxy tryptamine, therefore find Quetiapine metabolism and COMT
The relation of gene pleiomorphism is prior art urgent need to solve the problem.
Retrieval to existing document, the COMT gene SNP rs5993883 finding no the present invention is Quetiapine molecule mark
The relevant report of note thing.
Summary of the invention
For defect of the prior art, it is an object of the invention to provide a kind of detection quinoline sulfur based on rs5993883
The test kit of flat medication effect and using method thereof.
The present invention is achieved by the following technical solutions:
First aspect, the invention provides the nucleotide containing mononucleotide polymorphism site of a kind of separation, described core
The sequence of thuja acid is as shown in SEQ ID NO:6, and described mononucleotide polymorphism site is positioned at the 8375th,
Rs5993883 is T → G.
Second aspect, the invention provides a kind of nucleotide as the aforementioned test kit in preparation detection Quetiapine medication effect
In purposes.
The third aspect, the invention provides the nucleotide of a kind of separation, the sequence of described nucleotide such as SEQ ID NO:
Shown in 6 the 8375th, this site is T.
Fourth aspect, the invention provides a kind of test kit detecting Quetiapine medication effect, and described test kit includes:
The primer pair of the upstream and downstream design of the 8375th according to sequence as shown in SEQ ID NO:6.
Preferably, described primer to for wild primers to or mutant primers pair, wherein, described wild type draws
Thing to for:
Forward primer: 5'-gatgcGAAAGTTACTGAAAACATCTaGT-3'
Reverse primer: 5'-CTAGTGAGTTGTGTTTTGTTAATTG-3'；
Described mutant primers to for:
Forward primer: 5'-GAAAGTTACTGAAAACATCgTGT-3'
Reverse primer: 5'-CTAGTGAGTTGTGTTTTGTTAATTG-3'.
5th aspect, the invention provides the non-diagnostic purpose using method of a kind of test kit as the aforementioned, and it includes as follows
Step:
Step one, extracts sample DNA；
Step 2, utilizes described primer to expand, obtains amplified production；
Whether step 3, exist the mononucleotide polymorphism site as shown in SEQ ID NO:6 in detection sample
rs5993883。
Preferably, described step 3 uses DNA sequencing, sequencing by hybridization, enzymatic mispairing cutting, heteroduplex
Any one method in analysis, dot blot, oligonucleotide arrays, Mini-sequencing, molecular beacon.
Preferably, a length of 15-50bp of described primer.
Preferably, in step 2, the actual conditions of described amplification is as follows: reaction system cumulative volume is 20 μ l, its
In:
100μmol·L-1dNTPs；
50mmol·L-1KCL；
10mmol·L-1Tris-HCL, pH are 8.3；
1.5mmol·L-1MgCl2；
0.5U Taq archaeal dna polymerase；
20-50ng template DNA；
0.5μl10pM SEQ ID No.3；
0.5μl10pM SEQ ID No.4；
Distilled water complements to 20ul；
PCR reaction condition: 95 DEG C of 2mins；30×(94℃30s；58 DEG C of 30s, 72 DEG C of 30s) 72 DEG C of 5mins.
6th aspect, the invention provides the wild primers pair of a kind of SNP site for detection such as foregoing nucleotide,
Described primer to for:
Forward primer: 5'-gatgcGAAAGTTACTGAAAACATCTaGT-3'
Reverse primer: 5'-CTAGTGAGTTGTGTTTTGTTAATTG-3'.
7th aspect, the invention provides the mutant primers pair of a kind of SNP site for detection such as foregoing nucleotide,
It is characterized in that, described primer to for:
Forward primer: 5'-GAAAGTTACTGAAAACATCgTGT-3'
Reverse primer: 5'-CTAGTGAGTTGTGTTTTGTTAATTG-3'.
The sample that the present invention uses is from 995 schizophrenics of Shanghai Mental Health Center, age 18～60
Year.All participants are agreed to signature by family members on formal Informed Consent Form.
On the basis of above-mentioned, the present invention uses fragment length difference ApoE gene (FLDAS-PCR) typing
COMT gene SNP rs5993883 site and frequency distribution situation thereof are detected by technology.Have discovered that
The 8375th T → G polymorphism of COMT gene SNP rs5993883.
Compared with prior art, the present invention has a following beneficial effect:
The present invention is that in research population of China, the relation of COMT gene pleiomorphism and clinical drug safety is laid a good foundation,
Provide fundamental basis for clinical application individuation, the most also provide for new drug development based on pharmacogenomics theory and instruct
Foundation.
Detailed description of the invention
Below in conjunction with specific embodiment, the present invention is described in detail.Following example will assist in those skilled in the art
Member is further appreciated by the present invention, but limits the present invention the most in any form.It should be pointed out that, the common skill to this area
For art personnel, without departing from the inventive concept of the premise, it is also possible to make some deformation and improvement.These broadly fall into
Protection scope of the present invention.
Below in conjunction with specific embodiment, the present invention is expanded on further.Should be understood that these embodiments are merely to illustrate the present invention
Rather than restriction the scope of the present invention.The experimental technique of unreceipted actual conditions in the following example, usual more solito bar
The molecular cloning of part, such as Sambrook et al.: laboratory manual (New York:Cold Spring Harbor
Laboratory Press, 1989) condition described in, or according to the condition proposed by manufacturer.
The present invention relates to the detection side of the single nucleotide polymorphism of No. four intron SNP rs5993883 of COMT gene
Method, relates to separation nucleic acid and the primer being correlated with simultaneously.The present invention has had been surprisingly found that COMT gene by association analysis
No. four intron SNP rs5993883 can be as the molecular marked compound of Quetiapine, and this COMT gene the 4th includes
The sequence of son is as shown in SEQ ID NO:1, and wherein the 8375th exists single nucleotide polymorphism, i.e. SNP rs5993883.
The present invention is directed to this SNP rs5993883 and devise relevant primer pair.
The present invention uses Taqman-MGB probe technique to No. four intron SNP site of COMT gene and frequency thereof
Rate distribution situation is detected, and finds the 8375th T → G polymorphism of No. four intron of COMT gene.
Specifically, present invention SNP rs5993883 upstream and downstream design on No. four intron of COMT gene
Taqman-MGB primer；Taqman-MGB probe, the long 15-50bp of probe is designed between upstream and downstream primer；Then
With ABI7700 quantitative real time PCR Instrument, taken sample COMT gene SNP site rs5993883 is carried out typing, send out
Existing No. four intron SNP of COMT gene (i.e. the 8375th T → G polymorphism).
The present invention has substantial amounts of analytical technology to can be used for detecting whether site described in No. four intron of COMT gene deposits
In single nucleotide polymorphism；These technology include (but being not limited to): DNA sequencing, sequencing by hybridization；Enzymatic mispairing
Cutting, heteroduple analysis, dot blot, oligonucleotide arrays (DNA chip), Mini-sequencing, molecule letter
Mark etc., denaturing high-performance liquid chromatography (DHPLC).The detection method of the present invention is used for assessing individual COMT base
Relation because of No. four intron SNPrs5993883 polymorphism with Metabolism of Clozapine.Test sample for the present invention does not has
There is restriction especially, for detection SNP, can be the DNA extracted from the samples such as the blood separated, tissue
Or mRNA；For No. four intron activity of COMT gene, can be any containing COMT gene the 4th
The sample of intron, such as the blood etc. separated.
Described " isolated or purification " refers in genomic DNA level, utilizes primer each to expanding
The gene order of pleomorphism site and utilize purification kit that amplified production is purified.
The following is the specific implementation process to the present invention program:
The sample (specially blood sample) that the present embodiment uses is from 995 schizophrenias of Shanghai Mental Health Center
Disease patient, age 18～60 years old；All participants are agreed to signature by family members on formal Informed Consent Form.This enforcement
The cDNA sequence of No. four intron of COMT gene that example relates to is shown in SEQ ID NO:1, its coded aminoacid
Sequence is listed in SEQ ID NO:2；The genome sequence of No. four intron of COMT gene can obtain from GenBank
?.
Design of primers information:
Use Primer 5.0 software, with No. four intron of GenBank data base's COMT gene (ID:1312) with
And intron is stencil design pair of primers with intron junction sequence, Invitrogen company synthesize.
Primer information, the DNA sequence primer information of amplification No. four intron SNP site of COMT gene:
Wild primers to for:
Forward primer: 5'-gatgcGAAAGTTACTGAAAACATCTaGT-3'(SED ID NO:3)
Reverse primer: 5'-CTAGTGAGTTGTGTTTTGTTAATTG-3'；(SED ID NO:4)
Described mutant primers to for:
Forward primer: 5'-GAAAGTTACTGAAAACATCgTGT-3'(SED ID NO:5)
Reverse primer: 5'-CTAGTGAGTTGTGTTTTGTTAATTG-3'(SED ID NO:4)
PCR amplification condition: (the every reagent of system is provided by ABI company, it is also possible to obtain from disclosed channel)
Reaction system cumulative volume is 20 μ l, wherein:
100μmol·L-1dNTPs；
50mmol·L-1KCL；
10mmol·L-1Tris-HCL, pH are 8.3；
1.5mmol·L-1MgCl2；
0.5U Taq archaeal dna polymerase；
20-50ng template DNA；
0.5μl10pM SEQ ID No.3；
0.5μl10pM SEQ ID No.4；
Distilled water complements to 20ul；
PCR reaction condition: 95 DEG C of 2mins；30×(94℃30s；58 DEG C of 30s, 72 DEG C of 30s) 72 DEG C of 5mins.
After above-mentioned PCR has reacted, amplified production is silver staining after native polyacrylamide gel electrophoresis, permissible
Find that COMT gene SNP rs5993883 wild type (genotype is A) amplified production is than saltant type (genotype is G)
Many 5bp, therefore genotype be homozygous individual amplified production be single band, heterozygous individual be pair bands.Relatively find
COMT gene SNP rs5993883 has polymorphism (i.e. the 8375th T → G).Association analysis finds COMT base
Because the G genotype of SNP rs5993883 has significant individual variation before and after T genotype patient's quetiapine in treatment,
P value is 0.007 (being shown in Table 1).
The present invention is that in research population of China, the relation of COMT gene pleiomorphism and clinical drug safety is laid a good foundation,
Provide fundamental basis for clinical application individuation, the most also provide for new drug development based on pharmacogenomics theory and instruct
Foundation.
Table 1
Above the specific embodiment of the present invention is described.It is to be appreciated that the invention is not limited in
Stating particular implementation, those skilled in the art can make various deformation or amendment within the scope of the claims,
This has no effect on the flesh and blood of the present invention.
Claims (12)
1. the nucleotide containing mononucleotide polymorphism site separated, it is characterised in that described nucleotide
Sequence is as shown in SEQ ID NO:6, and described mononucleotide polymorphism site is positioned at the 8375th, and rs5993883 is
T→G。
2. a nucleotide as claimed in claim 1 purposes in the test kit of preparation detection Quetiapine medication effect.
3. one kind separate nucleotide, it is characterised in that the sequence of described nucleotide as shown in SEQ ID NO:6,
And the 8375th be T.
4. the test kit detecting Quetiapine medication effect, it is characterised in that described test kit includes: according to
The primer pair of the upstream and downstream design of the 8375th of sequence as shown in SEQ ID NO:6.
5. test kit as claimed in claim 4, is characterized in that, described primer to for wild primers to or saltant type
Primer pair, wherein, described wild primers to for:
Forward primer: 5'-gatgcGAAAGTTACTGAAAACATCTaGT-3'
Reverse primer: 5'-CTAGTGAGTTGTGTTTTGTTAATTG-3'；
Described mutant primers to for:
Forward primer: 5'-GAAAGTTACTGAAAACATCgTGT-3'
Reverse primer: 5'-CTAGTGAGTTGTGTTTTGTTAATTG-3'.
6. a non-diagnostic purpose using method for the test kit as described in any one of claim 4 and 5, its feature exists
In, comprise the steps:
Step one, extracts sample DNA；
Step 2, utilizes described primer to expand, obtains amplified production；
Whether step 3, exist the mononucleotide polymorphism site as shown in SEQ ID NO:6 in detection sample
rs5993883。
7. using method as claimed in claim 6, it is characterised in that described step 3 uses DNA sequencing, hybridization
Order-checking, enzymatic mispairing cutting, heteroduple analysis, dot blot, oligonucleotide arrays, Mini-sequencing, molecule
Any one method in beacon.
8. using method as claimed in claim 6, it is characterised in that step 3 comprises the steps: to use ABI7700
Quantitative real time PCR Instrument, carries out typing to the site rs5993883 of taken sample, detects the 8375th and no there is monokaryon
Nucleotide polymorphism.
9. using method as claimed in claim 6, it is characterised in that a length of 15-50bp of described primer.
10. using method as claimed in claim 6, it is characterised in that in step 2, the actual conditions of described amplification
As follows: reaction system cumulative volume is 20 μ l, wherein:
PCR amplification condition:
100μmol·L-1dNTPs；
50mmol·L-1KCL；
10mmol·L-1Tris-HCL, pH are 8.3；
1.5mmol·L-1MgCl2；
0.5U Taq archaeal dna polymerase；
20-50ng template DNA；
0.5μl10pM SEQ ID No.3；
0.5μl10pM SEQ ID No.4；
Distilled water complements to 20ul；
PCR reaction condition: 95 DEG C of 2mins；30×(94℃30s；58 DEG C of 30s, 72 DEG C of 30s) 72 DEG C of 5mins.
11. 1 kinds of wild primers pair being used for detecting the SNP site of nucleotide as claimed in claim 1, its feature exists
In, described primer to for:
Forward primer: 5'-gatgcGAAAGTTACTGAAAACATCTaGT-3'
Reverse primer: 5'-CTAGTGAGTTGTGTTTTGTTAATTG-3'.
12. 1 kinds for detecting the mutant primers pair of the SNP site of nucleotide as claimed in claim 1, its feature
Be, described primer to for:
Forward primer: 5'-GAAAGTTACTGAAAACATCgTGT-3'
Reverse primer: 5'-CTAGTGAGTTGTGTTTTGTTAATTG-3'.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610298301.6A CN105861685A (en) | 2016-05-06 | 2016-05-06 | Kit for testing Quetiapine application effect based on rs5993883 and application method of kit |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610298301.6A CN105861685A (en) | 2016-05-06 | 2016-05-06 | Kit for testing Quetiapine application effect based on rs5993883 and application method of kit |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105861685A true CN105861685A (en) | 2016-08-17 |
Family
ID=56630552
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610298301.6A Pending CN105861685A (en) | 2016-05-06 | 2016-05-06 | Kit for testing Quetiapine application effect based on rs5993883 and application method of kit |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105861685A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112301134A (en) * | 2019-07-29 | 2021-02-02 | 上海利康精准医疗技术有限公司 | Probe, primer and kit for detecting polymorphism of catechol-oxygen-methyltransferase gene |
-
2016
- 2016-05-06 CN CN201610298301.6A patent/CN105861685A/en active Pending
Non-Patent Citations (3)
| Title |
|---|
| GMI: "ss287550223", 《DBSNP DATABASE》 * |
| JOHAN DEN DUNNEN等: "homo sapiens catechol-O-methyltransferase(COMT), RefSeqGene(LRG_1010) on chromosome 22", 《GENBANK DATABASE》 * |
| XU Q等: "Association studies of genomic variants with treatment response to risperidone, clozapine, quetiapine and chlorpromazine in the Chinese Han population", 《THE PHARMACOGENOMICS JOURNAL》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112301134A (en) * | 2019-07-29 | 2021-02-02 | 上海利康精准医疗技术有限公司 | Probe, primer and kit for detecting polymorphism of catechol-oxygen-methyltransferase gene |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106591441B (en) | Alpha and/or beta-thalassemia mutation detection probe, method and chip based on whole gene capture sequencing and application | |
| CN106119363A (en) | SNP combination, detection method and test kit for the detection of antituberculotics hepatic injury susceptible genotype | |
| Barker et al. | Efficient detection of Alport syndrome COL4A5 mutations with multiplex genomic PCR‐SSCP | |
| CN106701987A (en) | PCR (polymerase chain reaction) amplification system for genotyping of three SNP (single-nucleotide polymorphism) loci related to human folic acid metabolism and detection kit | |
| CN109385482B (en) | SNP molecular marker related to lefteye flounder fertility and screening method and application thereof | |
| CN105861686A (en) | Kit for testing clozapine application effect based on rs2032582 and application method of kit | |
| CN101818195A (en) | Genetic marker by taking pig miR-27a precursor flanking sequence SNP as trait of litter size of pig and application | |
| Pichon et al. | Analysis and annotation of DNA methylation in two nonhuman primate species using the Infinium Human Methylation 450K and EPIC BeadChips | |
| CN106119244A (en) | The test kit of detection Kui sulfur flat medication effect based on rs6269 and using method thereof | |
| CN105861685A (en) | Kit for testing Quetiapine application effect based on rs5993883 and application method of kit | |
| AU2005314732B2 (en) | Method for identifying gene with varying expression levels | |
| EP0809696A1 (en) | Novel allele of human histamine h2 receptor and methods of detection of h2 receptor variants | |
| CN108517357B (en) | Kit for detecting sudden cardiac death-related SNP (single nucleotide polymorphism) on SCN5A gene related to sudden cardiac death and detection method thereof | |
| EP2041304A1 (en) | Rgs2 genotypes associated with extrapyramidal symptoms induced by antipsychotic medication | |
| CN106222268B (en) | POU1F1 haplotype molecular marker related to duck growth traits and application | |
| CN103013993B (en) | The method of primer and this primer Mass Spectrometer Method PIK3CA hotspot mutation | |
| CN105925679A (en) | Kit for detecting medication effects of clozapine and risperidone by virtue of rs4680 polymorphism | |
| CN101691612B (en) | Gene diagnostic kit for chicken flavor substances and using method thereof | |
| ES2445709T3 (en) | Method for the identification by molecular techniques of genetic variants that do not encode D (D-) antigen and encode altered C (C + W) antigen | |
| US20140141432A1 (en) | Method and kit for diagnosing glaucoma in dogs | |
| CN107574167B (en) | Hyriopsis cumingii microsatellite marker and application thereof | |
| CN105506090A (en) | Primer and method for detecting ADH1B gene*2 polymorphism | |
| Pulst | Neurogenetics | |
| CN110938681A (en) | Allele nucleic acid enrichment and detection method | |
| CN109797224B (en) | \28294Jgoose fat liver related A-FABP gene and molecular marking method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160817 |
|
| RJ01 | Rejection of invention patent application after publication |